Answering the Question: Why was Lepirudin discontinued?
•
4 min read
Up to 56% of patients receiving Lepirudin developed anti-lepirudin antibodies, a primary factor in its market withdrawal [1.3.4]. This article explains in-depth why was Lepirudin discontinued, exploring the clinical challenges and the shift towards safer anticoagulants for treating heparin-induced thrombocytopenia (HIT).
